	US 12,465,632 B2
	Purified capsular polysaccharides of Streptococcus pneumoniae
Rajendar Burki, Telangana (IN); Vivek Babu Kandimalla, Telangana (IN); Rajan Sriraman, Telangana (IN); Ramesh Venkat Matur, Telangana (IN); Narender Dev Mantena, Telangana (IN); Mahima Datla, Telangana (IN); and Veerapandu Sangareddy, Telangana (IN)
Assigned to Biological E Limited, (IN)
Filed by Biological E Limited, Telangana (IN)
Filed on Jun. 12, 2024, as Appl. No. 18/741,232.
Application 18/741,232 is a division of application No. 17/278,181, granted, now 12,048,739, previously published as PCT/IB2019/058036, filed on Sep. 23, 2019.
Prior Publication US 2024/0325516 A1, Oct. 3, 2024
Int. Cl. A61K 39/02 (2006.01); A61K 31/715 (2006.01); A61K 39/09 (2006.01); A61K 47/62 (2017.01); C08B 37/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/092 (2013.01) [A61K 31/715 (2013.01); A61K 47/62 (2017.08); C08B 37/0003 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/70 (2013.01)]

11 Claims

1. A pneumococcal conjugate vaccine comprising a 1-cyano-4-dimethylaminopyridine tetrafluoroborate (CDAP)-activated purified capsular polysaccharides from serotype 35B having an average molecular weight between 100 kDa and 500 kDa conjugated to PsaA, wherein the pneumococcal conjugate vaccine comprises a (w/w) percent ratio of protein to polysaccharide (protein/PS) of 0.7 to 1.2.